Premium
Aberrant IL ‐35 levels in patients with primary Sjogren's syndrome
Author(s) -
Guo Jie,
Gu Mingli,
Zhang Weiwei,
Liu Yun,
Qian Cheng,
Deng Ammei
Publication year - 2018
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12718
Subject(s) - cd19 , peripheral blood mononuclear cell , pathogenesis , flow cytometry , cytokine , antibody , immunology , messenger rna , microbiology and biotechnology , biology , medicine , endocrinology , gene , in vitro , biochemistry
Objective IL ‐35 is a newly discovered immunoregulatory cytokine that possesses the ability to inhibit CD 4 + effector T cells and alleviate autoimmune diseases. The objective of this study was to investigate IL ‐35 levels in patients with primary Sjogren's syndrome ( pSS ) and explore the roles of IL ‐35 in the pathogenesis of pSS . Methods Thirty‐four hospitalized patients with pSS were recruited, and 34 volunteers were enrolled as healthy controls. An ELISA was adopted to measure plasma IL ‐35 levels. The levels of P35 and EBI 3 mRNA s in peripheral blood mononuclear cells ( PBMC s) were determined using real‐time quantitative PCR . The percentage of CD 4 + EBI 3 + T cells and CD 19 + EBI 3 + B cells was analysed using flow cytometry. Correlations between IL ‐35 levels, P35 and EBI 3 mRNA s, numbers of CD 4 + EBI 3 + T cells, CD 19 + EBI 3 + B cells and clinical parameters were analysed. Results Significantly lower plasma IL ‐35 levels, P35 and EBI 3 mRNA levels, and percentages of CD 4 + EBI 3 + T cells but increased percentages of CD 19 + EBI 3 + B cells were observed in patients with pSS than in healthy controls. IL ‐35 levels, EBI 3 mRNA expression and the percentage of CD 4 + EBI 3 + T cells exhibited negative correlations with the ESSDAI score, whereas levels of the IL ‐35 protein and EBI 3 mRNA were negatively correlated with the ESR . Patients who were positive for anti‐ SSB antibodies presented with lower IL ‐35 levels and percentages of CD 4 + EBI 3 + T cells. Conclusions Based on these results, a decrease in the IL ‐35 levels may play an important role in the pathogenesis of pSS . IL ‐35 may act as a potential therapeutic agent against inflammation in patients with pSS .